

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**” or “**Alibaba Health**”) is pleased to announce the audited annual results of the Company and its subsidiaries (collectively referred to as the “**Group**”) for the year ended March 31, 2026 (the “**Reporting Period**” or “**FY2026**”) together with comparative figures for the preceding financial year (the “**Corresponding Period**”). The annual consolidated financial statements have been reviewed by the audit committee of the Company (the “**Audit Committee**”).

HIGHLIGHTS

During the Reporting Period, the Group achieved stable revenue growth, with total revenue reaching RMB34,255.1 million, representing a year-on-year increase of 12.0%. Net profit amounted to RMB1,936.3 million, up 35.2% year-on-year. Adjusted net profit amounted to RMB2,326.2 million, representing a year-on-year increase of 19.3%, and adjusted net profit margin improved from 6.4% to 6.8%.

During the Reporting Period, the Taobao and Tmall Healthcare Platform, operated by the Group, continued to deliver steady growth. The number of annual active users (“**AAU**”) — those who made one or more actual purchases on the Taobao Platform (including the Tmall Healthcare Platform) within the past 12 months — continued to increase. During the Reporting Period, the Group actively established itself as an “premiere online launch platform for innovative and specialty drugs” across multiple disease areas, further expanded strategic partnership with pharmaceutical companies. At the same time, the Group continued to evaluate and implement the integration of “localized services + Internet healthcare,” progressively building a closed-loop digital patient service ecosystem.

In 2026, to capitalise on the foundation of pharmaceutical e-commerce and Internet healthcare services, the Group has further expanded its strategic focus into building and developing smart healthcare infrastructure. Applying its in-depth knowledge in Chinese clinical terminology datasets, disease and drug taxonomies, and broad collection of data points from its Internet healthcare platform, the Group launched “Hydrion”^ (氫離子), a large model trained to serve the daily needs of doctors and other clinical and research professionals. Looking ahead, Alibaba Health will continue to foster the closed-loop ecosystem of “medicine, therapeutics, intelligence”^ (醫 — 藥 — 智), and harness technology to improve access to medical resources and extend their reach and applicability.

KEY FINANCIAL FIGURES

	For the year ended March 31,		
	2026	2025	Change
	RMB'000	RMB'000	%
Revenue	34,255,122	30,598,292	12.0
Gross profit	8,210,117	7,432,091	10.5
Profit for the year	1,936,342	1,432,014	35.2
Adjusted net profit ^(Note)	2,326,178	1,949,673	19.3

Note:

Adjusted net profit is based on the profit for the respective year after excluding non-operating profit or loss items such as share-based compensation expenses, change in fair value of equity investments at fair value through profit or loss (“FVPL”) (net of tax), gain on deemed disposal of associates (net of tax), gain or loss on partial disposal of associates (net of tax) and impairment of investments in associates (net of tax), and gain on partial disposal of FVPL (net of tax). With the exclusion of the impact of such items, which are not indicative of our key operational performance, investors can better compare our operational performance across various years.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

During the Reporting Period, the “Internet + Healthcare” sector continued to make progress, driven by policy guidance and technological innovation. The National Health Commission, together with other ministries, pressed forward with “demand-side management” reforms to drive high-quality, multi-tiered, and inclusive development across the healthcare industry. These reforms included optimizing medical insurance payment mechanisms, expanding the scope of Internet-based diagnosis and treatment, and encouraging innovative healthcare models. In November 2025, the National Healthcare Security Administration issued its “Guiding Opinions on Actively Promoting the Reform of Medical Insurance Payment Methods”[^] (《關於積極推進醫保支付方式改革的指導意見》). This confirmed that Internet healthcare services would qualify for medical insurance coverage, providing additional momentum for industry growth. In February 2026, the National Healthcare Security Administration released its “Implementation Rules for the Regulation on the Supervision and Administration of the Use of Medical Insurance Funds”[^] (《醫療保障基金使用監督管理條例實施細則》), strengthening oversight and standardizing how medical insurance funds are used. The Group’s digital tracking business has capitalized on these favourable regulatory reforms and initiatives, contributing to the robust and sustainable growth of the healthcare industry.

In the field of medical AI innovation, the National Health Commission issued the “Action Plan for the Development of Medical Artificial Intelligence Applications (2025–2027)”^ (《醫療人工智能應用發展行動計劃 (2025–2027年)》) in September 2025. The plan supports developing and adopting large medical models while driving innovation for a variety of use cases, such as in assisted diagnosis, treatment, medical research, and health management. Against this backdrop, Alibaba Health officially launched its first large model trained to serve the daily needs of doctors and other clinical and research professionals, “Hydrion”^ (氫離子), in May 2026. This marked a significant breakthrough in the Group’s strategic positioning in the medical AI field. During the Reporting Period, the Group maintained close alignment with national policy guidance, continued to increase investments in innovative drugs and AI-powered medical models, and achieved steady growth across all business segments.

During the Reporting Period, the Group’s total revenue amounted to RMB34,255.1 million, representing a year-on-year increase of 12.0%. Net profit amounted to RMB1,936.3 million, representing a year-on-year increase of 35.2%. Adjusted net profit amounted to RMB2,326.2 million, representing a year-on-year increase of 19.3%, and adjusted net profit margin improved from 6.4% to 6.8% year-on-year. During the Reporting Period, the Taobao and Tmall Healthcare Platform, operated by the Group, continued to deliver steady growth. The number of annual active users (“AAU”) — those who made one or more actual purchases on the Taobao Platform (including Tmall Healthcare Platform) within the past 12 months — continued to increase. Both the number of online proprietary merchants and the number of merchants transacting on the Tmall Healthcare Platform sustained rapid growth. The number of merchants with transactions increased by 26% year-on-year to 47,500, while the number of online SKUs with transactions increased by more than 25.8% to 27.5 million.

As at March 31, 2026, effective GMV of the Group’s direct online stores grew steadily, supported by continued increases in both the number of AAUs and the number of members in the direct-sales business. Average revenue per user (“ARPU”) for direct sales members increased by over 14% year-on-year, while the number of SKUs increased by 79% to 2.2 million. Meanwhile, the Group also enhanced its offerings for patients with chronic conditions. The cumulative number of paying chronic disease users grew 23% year-on-year, and the average duration of therapy (“DOT”) per user continued to grow year-on-year. During the Reporting Period, the Group further integrated and optimized its pharmaceutical logistics operations, as well as its combined network of general pharmaceutical and cold-chain warehouses. In particular, cold-chain warehouses were expanded to Guangzhou, Hangzhou, Tianjin, Kunshan, Zhengzhou, and Chengdu, completing the latest phase of network expansion. In the healthcare services segment, as at the end of the Reporting Period, the total number of licensed practitioners, pharmacists, and nutritionists contracted with the Group to provide online health consultation services increased 12.4% year-on-year to nearly 270,000, including those from Xiaolu TCM.

As the flagship healthcare platform of Alibaba Group Holding Limited (“**Alibaba Holding**”, together with its subsidiaries, the “**Alibaba Group**”), Alibaba Health continues to integrate AI technology with its end-to-end healthcare services to build an intelligent healthcare ecosystem that unifies online and offline capabilities. In 2026, the Group strengthened its pharmaceutical e-commerce and Internet healthcare foundations while expanding into smart healthcare infrastructure. Applying its in-depth knowledge in Chinese clinical terminology datasets, disease and drug taxonomies and broad collection of data points from its Internet healthcare platform, Alibaba Health launched “Hydrion”^ (氫離子), a large model trained to serve the daily needs of doctors and other clinical and research professionals. It is positioned as a reliable medical AI assistant with natural language search, evidence-based Q&A, literature review, Chinese-English comparison, and other such capabilities. Looking ahead, Alibaba Health will continue to foster the closed-loop ecosystem of “medicine, therapeutics, intelligence”^ (醫-藥-智), and harness technology to improve access to medical resources and extend their reach and applicability.

Pharmaceutical E-Commerce Business

The Group’s pharmaceutical e-commerce business continues to adopt a user-centric approach, fully leveraging its well-established brand strengths and resources built over years of operation. The Group combines its capabilities in e-commerce, big data, and cloud computing through an integrated model uniting the Tmall Healthcare Platform, pharmaceutical direct-sales business, and e-commerce advertising business. Through this foundation, it actively expands strategic partnership with upstream pharmaceutical, nutritional, healthcare, and medical device manufacturers and distributors to deliver a comprehensive suite of Internet-based health solutions.

- ***Pharmaceutical E-Commerce Platform Business — Tmall Healthcare Platform***

During the Reporting Period, as a leading online pharmaceutical and healthcare products service platform in China, the Tmall Healthcare Platform continued to leverage its platform advantages and digital capabilities to drive innovation and collaborate with industry partners. We explored new trends and emerging categories, expanded market boundaries, and closely tracked evolving user needs, aiming to provide users with more convenient, higher-quality healthcare services on the Tmall Healthcare Platform. During the Reporting Period, the Tmall Healthcare Platform further consolidated its position as the industry’s leading “premiere launch platform for new products,” supporting successful product introductions through a full-cycle support mechanism. Under the “Double 11 Super New Product Growth Program”^ (雙11超級新品增長計劃) in November 2025, the total transaction value of key supported new products exceeded RMB260.0 million, with total online exposure reaching tens of millions. The platform successfully launched seven new products, each recording transaction value exceeding RMB10.0 million, and 25 new products each exceeding RMB1.0 million. During the Reporting Period, the Taobao and Tmall Healthcare Platform, operated by the Group, maintained stable growth, with

AAU numbers continuing to increase. Both the number of online proprietary merchants and the number of merchants with transactions on the Tmall Healthcare Platform sustained rapid growth. Among them, the number of merchants with transactions increased by 26% year-on-year to 47,500, while the number of online SKUs with transactions increased by more than 25.8% year-on-year to 27.53 million. During the Reporting Period, the Group actively promoted merchants' business growth while providing them with more customized services. The advertising business continued to develop steadily (for further details, please refer to the announcement of the Group dated November 28, 2023).

- ***Pharmaceutical Direct Sales Business***

Adhering to its operational motto of “authenticity, affordability, professionalism, and reliability,” the Group’s pharmaceutical direct-sales business is committed to providing users across Tmall, Taobao, Alipay, Ele.me, and other platforms with comprehensive and affordable healthcare services covering prescription drugs, over-the-counter (“OTC”) medicines, nutritional supplements, medical devices, and contact lenses.

As at March 31, 2026, revenue from the pharmaceutical direct-sales business reached RMB29,665.0 million, representing a year-on-year increase of 13.6%. During the Reporting Period, Alibaba Health established a “first-launch platform for innovative and specialty drugs,” focusing on disease areas such as diabetes, hair loss, insomnia, and rhinitis, accelerating the introduction of new medicines while enhancing the accessibility of innovative treatments.

As at March 31, 2026, prescription drugs sales from the Group’s direct online stores maintained rapid growth, supported by continuous increases in AAUs and membership in the direct-sales business. ARPU for direct-sales members increased by over 14% year-on-year, and the number of SKUs under direct-sales business increased by 79% year-on-year to 2.2 million. Meanwhile, the Group also enhanced its offerings for patients with chronic conditions. In FY2026, the cumulative number of paying chronic disease users grew 23% year-on-year, and the average DOT per user continued to grow year-on-year. During the Reporting Period, the Group further integrated and optimized its pharmaceutical logistics operations, as well as its combined network of general pharmaceutical and cold-chain warehouses. In particular, cold-chain warehouses were expanded to Guangzhou, Hangzhou, Tianjin, Kunshan, Zhengzhou, and Chengdu, completing the latest phase of network expansion. In terms of delivery efficiency, while maintaining consistently high next-day delivery rates in existing cities, the Group further expanded half-day delivery services to Shanghai, Suzhou, Wuxi, Changzhou, Hangzhou, Ningbo, and Jiaxing, providing users with faster and more efficient medication delivery services.

Healthcare and Digital Services Business

During the Reporting Period, the Group continued to enhance the user experience of its professional healthcare services by providing an integrated online-to-offline system accessible through multiple platforms, including Tmall, Taobao, Alipay, AMap, DingTalk, Freshippo, and Quark. The services offered include traditional Chinese medicine (“TCM”), medical check-ups, consultations, appointment booking, vaccinations, dental care, mental health services, optometry, and nursing. As at March 31, 2026, the total number of licensed practitioners, pharmacists, and nutritionists contracted with the Group to provide online health consultation services increased by 12.4% year-on-year to nearly 270,000 (including Xiaolu TCM).

- ***Healthcare Services***

During the Reporting Period, the Group’s Internet hospital business continued to implement discipline-specific digital intelligent solutions, further deepening strategic cooperation with pharmaceutical companies to build a digital patient service ecosystem. During the Reporting Period, Alibaba Health entered a new round of strategic partnerships with pharmaceutical companies, including Novo Nordisk, with a focus on areas such as chronic disease patient services. In diabetes care, the Group leverages medical big-data analytics and AI-assisted diagnosis systems to deliver comprehensive smart healthcare solutions covering the full cycle of “prevention-diagnosis-management.” This model enables end-to-end digital services from online consultation through pharmaceutical delivery, strengthening treatment adherence while equipping doctors with continuous data support to facilitate personalized intervention. During the Reporting Period, in collaboration with Taobao Flash Shopping, Alibaba Health also launched a new “home rapid testing”^ (居家閃檢) service, which includes the “12-pathogen respiratory virus and bacteria test”^ (呼吸道病毒細菌12聯檢). The service was piloted in Beijing, Shanghai, Guangzhou, Tianjin, and Hangzhou, allowing users to conduct professional-grade testing at home and receive reports in approximately three hours. This provides a scientific basis for medication use and effectively alleviates pressure on healthcare services during flu seasons. Looking ahead, the Group will continue to introduce more professional healthcare service resources into instant-retail scenarios, accelerating the integration of “localized services + Internet healthcare” and working toward an integrated closed-loop service model covering “diagnosis, medicine, therapeutics”^ (檢-醫-藥). This initiative aims to provide users with more convenient and efficient localized healthcare services. During the Reporting Period, the Xiaolu TCM business also maintained steady growth. As at March 31, 2026, the number of registered TCM practitioners on Xiaolu TCM increased to 157,000, with further improvements in both network coverage and service quality. As the first platform in the industry to integrate TCM services into a large-model ecosystem, Xiaolu TCM continued to deepen its AI deployment, continuously optimizing medical consultation, medication access and other services.

- ***Digital Tracking Business***

With the continued implementation of end-to-end drug traceability policies by national and local drug regulatory authorities, as well as tracking code collection by the National Healthcare Security Administration across designated medical institutions and retail pharmacies, Alibaba Health’s “Ma Shang Fang Xin”^ (碼上放心) tracking platform has continued to provide efficient and cost-effective traceability services for pharmaceutical manufacturers and wholesalers. To date, the platform has provided traceability compliance services to pharmaceutical manufacturing and wholesale logistics enterprises, retail pharmacies, and secondary-tier medical institutions, forming the industry’s most extensive collaborative network of pharmaceutical enterprises based on traceability services. “Ma Shang Fang Xin” leverages its traceability service network and standardized “one object, one code” data system to track each pharmaceutical product throughout the supply chain. Leveraging this network, the platform has established deep partnerships with more than 1,300 leading pharmaceutical companies. The platform also continues to provide digital services such as digital marketing, channel management, distribution tracking, inventory management, and patient education.

The “Ma Shang Fang Xin” platform has also launched digital solutions for pharmaceutical circulation and electronic exchange services for first-time business documentation. To date, over 3,000 manufacturers and more than 11,000 distribution enterprises have used the platform to facilitate electronic circulation of drug inspection reports. Looking ahead, the Group will continue to promote sustainable and responsible development across the industry while further unlocking the collaborative value of its enterprise network.

In 2026, Alibaba Health strengthened its pharmaceutical e-commerce and Internet healthcare foundations while expanding into smart healthcare infrastructure. In May 2026, Alibaba Health officially launched a large model trained to serve the daily needs of doctors and other clinical and research professionals, “Hydrion”^ (氫離子), positioned as a “reliable medical AI assistant”. Built on the “Qwen”^ (通義千問) model, “Hydrion” integrates tens of millions of medical literature resources, clinical guidelines, and authoritative datasets, aggregating more than 500 billion medical data points. The model is designed to support doctors through natural language search, evidence-based Q&A, literature review, Chinese-English comparison, and other such capabilities. Its differentiated advantages include low response latency, reduced hallucination rates, and end-to-end, evidence-based traceability across multiple application scenarios. Looking ahead, Alibaba Health will continue to foster the closed-loop ecosystem of “medicine, therapeutics, intelligence”^ (醫-藥-智), and harness technology to improve access to medical resources and extend their reach and applicability.

Public Service

During the Reporting Period, the Group continued to fulfill its corporate social responsibility, maintaining a strong focus on improving healthcare accessibility for vulnerable groups — including minors, the elderly, and residents in remote areas — and addressing social and livelihood challenges arising from uneven distribution of healthcare resources. In China, more than 20 million rare disease patients have long faced a dual burden: high disease costs compounded by limited access to affordable treatment. To better support these patients, Alibaba Health further upgraded its “Care Campaign for Lemon Babies”[^] (檸檬寶寶關愛行動) (a targeted assistance program for methylmalonic acidemia and propionic acidemia) into the broader “Rare Disease Care Initiative”[^] (罕見病關愛行動) in fiscal year 2026. Leveraging its platform capabilities and collaborating with public welfare organizations, medical institutions, and other ecosystem partners, the initiative established an integrated service model covering “screening-diagnosis-treatment-rehabilitation management.” With the support of provincial-level newborn screening centers, Alibaba Health and leading medical experts provided clinical and technical training to more than 800 healthcare professionals within the national newborn screening system, enhancing regional diagnosis and treatment capabilities. The initiative also distributed rare disease care packages to over 1,300 children with genetic metabolic disorders and promoted more scientific family caregiving through patient education and outreach programs. As at March 31, 2026, the initiative covered 18 types of rare diseases, aiding more than 2,500 patients through the “Rare Disease Care Platform.” The program has cumulatively reduced medical expenses by nearly RMB7.0 million, with total public-welfare investment exceeding RMB10.8 million. Building on its platform-based solutions, Alibaba Health will continue striving to deliver more accessible treatment solutions, ensure a stable supply of pharmaceuticals, and strengthen the comprehensive end-to-end management services for rare disease patients.

During the Reporting Period, Alibaba Health joined forces with the China Aging Development Foundation, Alibaba Foundation, and multiple pharmaceutical partners to launch the “Silver Age Care • Health Guardian”[^] (銀齡關愛•健康護航) initiative. This public-welfare program aims to build a protective health barrier for elderly residents in rural areas and promote the development of healthy villages through three core measures: medication donations, expert outreach, and healthcare-talent incubation. On December 26, 2025, the “Health Welfare Society” Public Welfare Cloud Pharmacy Initiative, jointly launched by Alibaba Health, the People’s Government of Foping County, Health Welfare Society, and Alibaba, with support from numerous charitable pharmaceutical companies, was officially implemented in Foping County, Shaanxi Province. The project adopted a “demand-based donation” approach and delivered 1,330 boxes of urgently needed medicines to primary healthcare institutions in Foping County, extending high-quality medical resources to underserved rural communities and directly benefiting more than 40,000 residents.

Future Prospects

As the industry's leading digital health management company and the flagship healthcare platform of Alibaba Group, Alibaba Health remains committed to deeply integrating AI technologies with its end-to-end healthcare service capabilities to build an intelligent, interconnected healthcare ecosystem that seamlessly links online and offline services. Looking ahead, the Group will maintain its user-centric focus, leveraging AI to enhance the accessibility of pharmaceutical and healthcare products, improve service efficiency, and explore new frontiers under the "AI + Healthcare" model.

FINANCIAL REVIEW

The key financial data of the Group for the years ended March 31, 2026 and 2025 is summarized as follows:

	2026	2025	Change
	<i>RMB'000</i>	<i>RMB'000</i>	%
Revenue	34,255,122	30,598,292	12.0
Gross profit	8,210,117	7,432,091	10.5
Gross profit margin	24.0%	24.3%	N/A
Fulfilment	(2,760,223)	(2,567,707)	7.5
Selling and marketing expenses	(2,451,996)	(2,258,374)	8.6
Administrative expenses	(373,363)	(407,432)	(8.4)
Product development expenses	(788,347)	(720,053)	9.5
Other income and gains	960,541	663,236	44.8
Other expenses and losses	(523,273)	(514,521)	1.7
Finance costs	(1,402)	(2,609)	(46.3)
Share of losses of a joint venture	(423)	(19,136)	(97.8)
Share of profits/(losses) of associates	2,589	(45,527)	N/A
Income tax expense	(337,878)	(127,954)	164.1
Profit for the year	1,936,342	1,432,014	35.2
NON-HKFRS ADJUSTMENTS			
Adjusted net profit	2,326,178	1,949,673	19.3

— Revenue

Revenue of the Group for the Reporting Period amounted to RMB34,255,122,000, representing an increase of RMB3,656,830,000 or 12.0% as compared with RMB30,598,292,000 for the Corresponding Period. The increase in revenue was mainly attributable to the steady development of the pharmaceutical direct sales business and healthcare and digital services during the Reporting Period.

— **Pharmaceutical Direct Sales Business**

The pharmaceutical direct sales business of the Group primarily comprises the direct business-to-customer (“B2C”) retail, related advertising business and the business-to-business (“B2B”) centralized procurement and distribution business. During the Reporting Period, the overall revenue from pharmaceutical direct sales business reached RMB29,664,989,000, representing an increase of 13.6% year-on-year. The growth in revenue from the pharmaceutical direct sales business was mainly attributable to the constant enrichment of categories of goods sold through the direct B2C retail and SKUs, as well as the continuous optimization of user experience by adopting a number of measures, such as improving information security and providing more professional consultation services.

— **Pharmaceutical E-commerce Platform Business**

The pharmaceutical e-commerce platform business of the Group comprises (i) the e-commerce platform business acquired from Alibaba Group (including categories of, among others, pharmaceutical products, healthcare food, medical devices, adult and family planning products and contact lenses); (ii) the provision of outsourced services to Tmall Healthcare Platform (in respect of categories other than those that have already been acquired) and (iii) new pharmaceutical retail business. At the same time, the integration of its marketing review services and value-added services has established a complete solution loop for health brand merchant solutions, further enhancing the operational completeness of platform model. During the Reporting Period, total revenue of the pharmaceutical e-commerce platform business amounted to RMB3,638,466,000, representing an increase of 1.4% year-on-year.

— **Healthcare and Digital Services Business**

During the Reporting Period, the Group continued to enhance user experience of professional healthcare services by providing its users with a seamless online-to-offline healthcare service (including TCM, medical checkups, testing, medical consultation and appointment-booking) through a variety of channels such as Tmall, Taobao and Alipay. Digital services business includes tracking business. “Ma Shang Fang Xin”^ (碼上放心), the Group’s proprietary tracking platform, continued to grow steadily, by offering more value-added services with further penetration into the area of distribution and increasing the coverage of retail terminals. During the Reporting Period, the revenue generated from the healthcare and digital services business increased by 7.5% year-on-year to RMB951,667,000.

— **Gross profit and gross profit margin**

The Group recorded a gross profit of RMB8,210,117,000 for the Reporting Period, representing an increase of RMB778,026,000 or 10.5% from RMB7,432,091,000 for the Corresponding Period. Gross profit margin for the Reporting Period was 24.0%, representing a decrease of 0.3 percentage points from 24.3% for the Corresponding Period. This was mainly due to the Group's investment in competitive pricing and promotional activities during the Reporting Period.

— **Fulfillment**

Warehousing, logistics, operation and customer service costs incurred by the Group's pharmaceutical direct sales business were included in fulfillment costs. Fulfillment expenses for the Reporting Period amounted to RMB2,760,223,000, representing an increase of RMB192,516,000 or 7.5% from RMB2,567,707,000 for the Corresponding Period. During the Reporting Period, fulfillment costs as a proportion of the revenue generated from pharmaceutical direct sales business decreased by approximately 0.5 percentage points to 9.3%, as compared with 9.8% for the Corresponding Period, reflecting higher operational efficiencies achieved by the Group in areas such as warehousing, logistics and customer service.

— **Selling and marketing expenses**

Selling and marketing expenses for the Reporting Period amounted to RMB2,451,996,000, representing an increase of RMB193,622,000 or 8.6% compared with RMB2,258,374,000 for the Corresponding Period. The selling and marketing expenses as a proportion of the Group's total revenue for the Reporting Period decreased to 7.2% from 7.4% as compared with the Corresponding Period, benefiting from the continued economies of scale.

— **Administrative expenses**

Administrative expenses for the Reporting Period amounted to RMB373,363,000, representing a decrease of RMB34,069,000 or 8.4% as compared with RMB407,432,000 for the Corresponding Period. The administrative expenses as a proportion of the Group's total revenue for the Reporting Period decreased to 1.1% from 1.3% as recorded for the Corresponding Period, which was mainly due to optimization of cost controls and sustained economies of scale.

— **Product development expenses**

Product development expenses for the Reporting Period amounted to RMB788,347,000, representing an increase of RMB68,294,000 or 9.5% as compared with RMB720,053,000 for the Corresponding Period. The product development expenses as a proportion of the Group's total revenue for the Reporting Period decreased to 2.3% from 2.4% as recorded for the Corresponding Period, which was mainly due to the investment in large language models to provide healthcare services during the Reporting Period.

— **Other income and gains**

Other income and gains for the Reporting Period amounted to RMB960,541,000, which primarily comprised interest income, investment disposal gains, and government grants incurred during the year. The increase from RMB663,236,000 for the Corresponding Period was mainly due to the increase in gain on disposal of investments for the period.

— **Other expenses and losses**

During the Reporting Period, other expenses and losses amounted to RMB523,273,000, which primarily comprised the fair value losses of financial assets held and the impairment amount incurred by investments in associates. The increase of RMB8,752,000 from RMB514,521,000 in the Corresponding Period remained relatively stable.

— **Share of profits or losses of a joint venture**

Share of profits or losses of a joint venture represents the share of net operating results of the joint venture held as to 13.72% by the Group, Jiangsu Zijin Hongyun Health Industry Investment Partnership (Limited Partnership)^ (江蘇紫金弘雲健康產業投資合夥企業(有限合夥)). For the Reporting Period, the Group's share of losses of a joint venture amounted to RMB423,000, as compared with losses of RMB19,136,000 for the Corresponding Period.

— **Share of losses of associates**

The Group actively invests in the healthcare segment. The Group's share of profits of associates for the Reporting Period amounted to RMB2,589,000, representing a decrease in loss of RMB48,116,000 as compared with losses of RMB45,527,000 for the Corresponding Period.

— **Non-Hong Kong Financial Reporting Standard indicator in relation to profit for the Year: Adjusted net profit**

The Group's profit for the Reporting Period amounted to RMB1,936,342,000, as compared with a profit of RMB1,432,014,000 for the Corresponding Period. The Group's adjusted net profit for the Reporting Period amounted to RMB2,326,178,000, as compared with an adjusted net profit of RMB1,949,673,000 for the Corresponding Period. Adjusted net profit is based on the profit for the Reporting Period after excluding non-operating profit or loss items such as share-based compensation expenses, changes in fair value of equity investments at FVPL, net of tax, gain on deemed disposal of investments in associates, net of tax, gains or losses on partial disposal of associates, net of tax and impairment of investments in associates, net of tax and gain on partial disposal of equity investments at FVPL, net of tax. The increase of RMB376,505,000 in the adjusted net profit for the Reporting Period as compared with the previous financial year was mainly attributable to the continuous growth in the number of users on pharmaceutical direct sales business platforms, the operation refinement of the Group's business which has enhanced its operational efficiency, and the improvement in efficiency and cost sharing driven by the economies of scale on the platform.

To supplement the Group's consolidated financial statements presented in accordance with Hong Kong Financial Reporting Standards (“**HKFRSs**”), the Group has also reported its adjusted net profit, which is not required under, or presented in accordance with, HKFRSs, as an additional financial indicator. The Group believes that presenting the non-HKFRS indicator together with the relevant HKFRS indicator will facilitate investors in comparing its operational performance across various periods by removing the potential impact of items which its management considers as not indicative of its operational performance. The Group believes that the non-HKFRS indicator provides investors and others with helpful information to understand and assess its consolidated operational results in the same way as its management does. However, the presentation of adjusted net profit may not be comparable with similar indicators presented by other companies. Such non-HKFRS indicator has its limitations as an analytical tool, and it should not be considered as independent of the operational results or financial position presented under HKFRSs, or as a substitute for analyzing the relevant operational results or financial position. In addition, the definition of such non-HKFRS Financial indicator may differ from the definitions of similar indicators used by other companies.

The table below provides the adjustments made to the most direct and comparable financial indicator calculated and presented in accordance with HKFRSs (i.e. profit for the year) in arriving at the adjusted net profit (a non-HKFRS measure) for the years ended March 31, 2026 and 2025:

	For the year ended March 31,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
Profit for the year	1,936,342	1,432,014
Excluding		
— Share-based compensation expenses	162,124	224,535
— Fair value losses/(gain) on equity investments at FVPL, net of tax	402,578	(42,847)
— Gain on deemed disposal of associates, net of tax	(169,631)	(1,969)
— Loss/(gain) on partial disposal of associates, net of tax	(40,032)	10,209
— Impairment of investments in associates, net of tax	94,478	327,731
— Gain on partial disposal of FVPL, net of tax	(59,681)	—
	<hr/>	<hr/>
Adjusted net profit (non-HKFRS measure)	<u>2,326,178</u>	<u>1,949,673</u>

FINANCIAL RESOURCES, LIQUIDITY AND FOREIGN EXCHANGE EXPOSURES

For the Reporting Period, the Group met its cash requirements primarily through cash generated from operating activities. The Group's cash and cash equivalents as stated in the consolidated statement of cash flows and cash and bank deposits as stated in the consolidated statement of financial position mainly comprise cash on hand and at banks and highly liquid time deposits with a maturity of generally within three months when acquired. As at March 31, 2026 and March 31, 2025, the Group's cash and cash equivalents amounted to RMB5,434,097,000 and RMB2,218,296,000, respectively.

Cash flows of the Group for the years ended March 31, 2026 and 2025 were as follows:

	For the year ended March 31,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
Net cash flows generated from operating activities	1,236,633	1,395,033
Net cash flows generated from/(used in) investing activities	2,021,028	(2,596,482)
Net cash flows used in financing activities	(14,222)	(72,517)
Net increase/(decrease) in cash and cash equivalents	3,243,439	(1,273,966)
Cash and cash equivalents at the beginning of the year	2,218,296	3,490,169
Effects of exchange rate changes	(27,638)	2,093
Cash and cash equivalents as stated in the statement of cash flows and cash and bank deposits as stated in the statement of financial position at the end of the year	<u>5,434,097</u>	<u>2,218,296</u>

Net cash flows generated from operating activities

For the Reporting Period, net cash flows generated from operating activities amounted to RMB1,236,633,000 primarily attributable to profit before income tax from continuing operations of RMB2,274,220,000, as adjusted for: (i) non-cash or non-operating activities expense items, which primarily comprised the addition of share-based compensation expenses of RMB162,124,000, the addition of depreciation and amortization of RMB53,241,000, the addition of losses of financial assets at FVPL of RMB415,103,000, the deduction of bank interest income of RMB463,430,000, the addition of impairment of investments in associates of RMB94,478,000, and the deduction of gain on deemed disposal of associates of RMB226,176,000; (ii) changes in working capital, which primarily comprised an increase in trade and bills payables of RMB177,393,000, an increase in prepayments, other receivables and other assets of RMB428,484,000, a decrease in other payables and accruals of RMB5,892,000, an increase in contract liabilities of RMB157,385,000, an increase in inventories of RMB564,267,000, and an increase in trade receivables of RMB214,342,000, a decrease in restricted funds of RMB15,549,000, and a decrease in the payment of Chinese mainland corporate income tax of RMB332,124,000; and (iii) the addition of receipt of interest of RMB228,205,000.

Net cash flows generated from investing activities

For the Reporting Period, net cash generated from investing activities amounted to RMB2,021,028,000 which was primarily attributable to (i) placement of short-term time deposits with original maturities over three months when acquired of RMB4,543,687,000; (ii) withdrawal of short-term time deposits with original maturity over three months when acquired of RMB6,238,510,000; (iii) purchase of financial assets at fair value through profit or loss of RMB705,947,000; (iv) proceeds from maturity of short-term structured wealth management products of RMB496,598,000; (v) proceeds from partial disposal of equity interests in associates of RMB142,543,000 and (vi) receipt of interest income of RMB227,935,000 during the Reporting Period. As at March 31, 2026, each of such subscription of placement of time deposits, subscription of short-term structured wealth management products and disposal of short-term structured wealth management products (both on a standalone and an aggregated basis) has a value of less than 5% of all applicable percentage ratios of the Group and none of such products constituted a notifiable transaction of the Company.

Net cash flows used in financing activities

For the Reporting Period, net cash flows used in financing activities was RMB14,222,000, which was primarily attributable to the principal portion of lease payments of RMB24,978,000 and the payment of RMB10,756,000 for repurchase of shares of the Company by the trustee of the share award scheme of the Company during the Reporting Period.

Gearing ratio

As at March 31, 2026, the Group did not have any borrowings, and hence no gearing ratio was shown (March 31, 2025: Nil).

Charges on assets and contingent liabilities

As at March 31, 2026, the Group did not have any material contingent liabilities and had not pledged any Group assets for bank loans and banking facilities.

Liquidity

The Group's operations and transactions are principally conducted in the PRC. The Group prudently managed its treasury functions and maintained a healthy liquidity position throughout the Reporting Period. The Board closely monitors the Group's liquidity position to ensure that the liquidity structure of our assets, liabilities and other commitments can meet the Group's funding requirements from time to time.

Foreign exchange exposures

Except for a certain amount of bank balances and cash, most of the Group's bank balances and cash are placed in fixed deposits and are denominated in Hong Kong dollars, Renminbi and United States dollars, while other assets and liabilities are mainly denominated in either Hong Kong dollars or Renminbi. The Group changed its presentation currency from Hong Kong dollars to Renminbi starting from the year ended March 31, 2016 to better reflect its operations in the PRC and to be consistent with the internal reporting portfolio reviewed by the Directors. The Group does not have foreign exchange hedging policy, but the management will continue to closely monitor exchange rate fluctuations and will take appropriate measures to keep foreign exchange risk exposure to the minimum. The Group does not use any financial instruments for hedging purposes.

EMPLOYEES AND REMUNERATION POLICIES

The number of full-time employees of the Group as at March 31, 2026 was 1,429 (March 31, 2025: 1,364). Total staff costs of the Group for the Reporting Period amounted to RMB950.8 million (for the Corresponding Period: RMB1,067.9 million).

The Group's policy is to maintain a competitive pay structure and its employees are rewarded based on their performance.

The Group also adopted the 2014 Share Award Scheme (the “**2014 Share Award Scheme**”) as approved by the shareholders of the Company (the “**Shareholders**”) on November 24, 2014 and amended on August 11, 2023. The Company further adopted the 2024 Share Award Scheme (the “**2024 Share Award Scheme**”) pursuant to Chapter 17 of the Listing Rules on August 30, 2024, the terms of which are largely similar in material respects to the terms of the 2014 Share Award Scheme to ensure the consistent practice of share awards of the Group. Pursuant to the 2024 Share Award Scheme, the Board may grant awards in the form of restricted share units (“**RSUs**”) or options to eligible participants, including the Directors, the directors of the Company's subsidiaries, the employees of the Group or any other persons who, as determined by the Board in its absolute discretion, have contributed or will contribute to the Group.

Upon adoption of the 2024 Share Award Scheme, the 2014 Share Award Scheme was terminated in order to avoid administrative inconvenience. As such, upon adoption of the 2024 Share Award Scheme, no further share awards may be offered or granted under the 2014 Share Award Scheme, but in all other respects the terms of the 2014 Share Award Scheme shall remain in full force and effect. Further, the outstanding options and RSUs granted pursuant to the 2014 Share Award Scheme, which remain unvested or which have vested but not yet been exercised or in respect of which shares not yet issued to the participants at the time of its termination, shall remain in full force and effect.

SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Company has its own treasury policy setting out the selection guidelines and relevant approval procedures for acceptable short-term investments and financial assets with reference to its risk management policy. According to such treasury policy, the Company can invest in products including non-equity financial asset investments with strong liquidity which can be realized either at any time or within a short period of time. According to the Company's prevailing approval procedures, any investment decision related to financial assets shall be approved by the financial and treasury manager of the Company, and shall, depending on the size of the investment, be approved by the financial controller or chief financial officer. As at March 31, 2026, the Company's short-term investments at FVPL amounted to approximately RMB300.4 million (balance as at March 31, 2025: RMB263.6 million).

During the Reporting Period, the Group did not have any significant investments nor did the Group carry out any material acquisitions and disposals of subsidiaries, associates and joint ventures.

FINAL DIVIDEND AND SPECIAL DIVIDEND

The Board recommends the payment of a final dividend of RMB5.95 cents per share in cash (the "**Final Dividend**") and a special dividend of RMB13.52 cents per share in cash (the "**Special Dividend**") for the year ended March 31, 2026 (for the year ended March 31, 2025: Final Dividend of nil per share in cash and Special Dividend of nil per share), subject to approval by the Shareholders at the forthcoming annual general meeting (the "**Annual General Meeting**"). If approved at the Annual General Meeting, the proposed Final Dividend and Special Dividend will be paid in Hong Kong dollars, such amount to be calculated by reference to the middle rate published by the People's Bank of China for the conversion of Renminbi to Hong Kong dollars as at the date of Annual General Meeting. If approved at the Annual General Meeting, the Final Dividend and the Special Dividend are expected to be paid on Wednesday, September 2, 2026 to the Shareholders whose names appear on the Company's register of members at the close of business on Thursday, August 13, 2026, being the record date for determining the entitlement of the Shareholders to the Final Dividend and the Special Dividend.

In order to qualify for the Final Dividend and the Special Dividend (subject to Shareholders' approval at the Annual General Meeting), all duly completed transfer documents accompanied by the relevant share certificates must be lodged for registration with the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on Thursday, August 13, 2026.

The Company does not hold any treasury shares (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited), and treasury shares, if any, would not receive the dividends or distributions.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

There are no significant events of the Group subsequent to March 31, 2026 and up to the date of this announcement.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

Year ended March 31, 2026

	Notes	2026 RMB'000	2025 RMB'000
REVENUE	4	34,255,122	30,598,292
Cost of sales		<u>(26,045,005)</u>	<u>(23,166,201)</u>
Gross profit		8,210,117	7,432,091
Other income and gains	4	960,541	663,236
Operating expenses			
Fulfilment		(2,760,223)	(2,567,707)
Selling and marketing expenses		(2,451,996)	(2,258,374)
Administrative expenses		(373,363)	(407,432)
Product development expenses		(788,347)	(720,053)
Other expenses and losses		(523,273)	(514,521)
Finance costs		(1,402)	(2,609)
Share of profits/(losses) of:			
A joint venture		(423)	(19,136)
Associates		<u>2,589</u>	<u>(45,527)</u>
PROFIT BEFORE TAX	5	2,274,220	1,559,968
Income tax expense	6	<u>(337,878)</u>	<u>(127,954)</u>
PROFIT FOR THE YEAR		<u>1,936,342</u>	<u>1,432,014</u>
Attributable to:			
Owners of the parent		1,936,162	1,432,427
Non-controlling interests		<u>180</u>	<u>(413)</u>
		<u>1,936,342</u>	<u>1,432,014</u>
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	7		
Basic		<u>RMB12.02 cents</u>	<u>RMB8.91 cents</u>
Diluted		<u>RMB11.95 cents</u>	<u>RMB8.88 cents</u>

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Year ended March 31, 2026

	<i>Note</i>	2026 RMB'000	2025 <i>RMB'000</i>
PROFIT FOR THE YEAR		<u>1,936,342</u>	<u>1,432,014</u>
OTHER COMPREHENSIVE INCOME/(LOSS)			
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of the financial statements of subsidiaries with non-RMB functional currencies		<u>(97,839)</u>	<u>334</u>
Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of the financial statements of the Company		(401,656)	86,717
Equity investments at fair value through other comprehensive income:			
Changes in fair value		(46,594)	(21,737)
Gain of disposal		<u>3,347</u>	<u>—</u>
		<u>(43,247)</u>	<u>(21,737)</u>
Associates:			
Share of other comprehensive loss		—	(283)
Income tax effect		<u>—</u>	<u>71</u>
		—	(212)
Total other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods, net of tax		<u>(444,903)</u>	<u>64,768</u>

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (CONTINUED)*Year ended March 31, 2026*

	<i>Note</i>	2026 RMB'000	2025 <i>RMB'000</i>
TOTAL OTHER COMPREHENSIVE INCOME/ (LOSS) FOR THE YEAR, NET OF TAX		<u>(542,742)</u>	<u>65,102</u>
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		<u>1,393,600</u>	<u>1,497,116</u>
Attributable to:			
Owners of the parent		1,393,420	1,497,529
Non-controlling interests		<u>180</u>	<u>(413)</u>
		<u>1,393,600</u>	<u>1,497,116</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

March 31, 2026

	<i>Notes</i>	2026 RMB'000	2025 <i>RMB'000</i>
NON-CURRENT ASSETS			
Property and equipment		26,793	35,693
Right-of-use assets		60,830	34,027
Goodwill		805,337	810,853
Other intangible assets		258,229	275,220
Investment in a joint venture		184,526	208,966
Investments in associates		717,033	1,521,014
Equity investments designated at fair value through other comprehensive income		138,684	97,588
Financial assets at fair value through profit or loss		1,974,932	1,622,162
Other receivables and other assets		134,771	93,480
Deferred tax assets		20,733	50,821
Long-term time deposits		3,348,955	4,152,413
Total non-current assets		7,670,823	8,902,237
CURRENT ASSETS			
Inventories		1,848,739	1,415,220
Trade and bills receivables	9	1,265,890	1,052,523
Prepayments, other receivables and other assets		1,789,510	1,389,303
Prepaid tax		33,927	16,048
Financial assets at fair value through profit or loss		300,414	263,621
Restricted cash		318,792	303,243
Short-term time deposits		4,430,913	5,617,926
Cash and bank deposits		5,434,097	2,218,296
Total current assets		15,422,282	12,276,180
CURRENT LIABILITIES			
Trade and bills payables	10	3,029,774	2,852,381
Other payables and accruals		1,059,573	1,047,903
Contract liabilities		852,480	695,095
Lease liabilities		29,578	10,579
Tax payable		121,872	136,214
Total current liabilities		5,093,277	4,742,172

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

	<i>Notes</i>	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
NET CURRENT ASSETS		<u>10,329,005</u>	<u>7,534,008</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>17,999,828</u>	<u>16,436,245</u>
NON-CURRENT LIABILITIES			
Lease liabilities		30,177	24,936
Deferred tax liabilities		<u>113,086</u>	<u>98,149</u>
Total non-current liabilities		<u>143,263</u>	<u>123,085</u>
Net assets		<u>17,856,565</u>	<u>16,313,160</u>
EQUITY			
Equity attributable to owners of the parent			
Share capital		143,546	142,790
Treasury shares		(8,531)	(52,600)
Reserves		<u>17,720,389</u>	<u>16,221,989</u>
		17,855,404	16,312,179
Non-controlling interests		<u>1,161</u>	<u>981</u>
Total equity		<u>17,856,565</u>	<u>16,313,160</u>

NOTES TO FINANCIAL STATEMENTS

March 31, 2026

1. BASIS OF PREPARATION

These consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards (“HKASs”) and Interpretations) as issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”) and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for financial investments at fair value through profit or loss (“FVPL”) and equity investments designated at fair value through other comprehensive income (“FVOCI”), which have been measured at fair value. These financial statements are presented in Renminbi (“RMB”) and all values are rounded to the nearest thousand except when otherwise indicated.

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted amendments to HKAS 21 *Lack of Exchangeability* for the first time for the current year’s financial statements. The Group has not early adopted any other standard or amendment that has been issued but is not yet effective.

Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted in and the functional currencies of overseas subsidiaries, joint ventures and associates for translation into the Group’s presentation currency were exchangeable, the amendments did not have any impact on the Group’s financial statements.

In addition, the HKICPA has issued amendments to Illustrative Examples on HKFRS 7, HKFRS 18, HKAS 1, HKAS 8, HKAS 36 and HKAS 37 *Disclosures about Uncertainties in the Financial Statements*, which added illustrative examples in the corresponding HKFRS Accounting Standards. These examples reflect existing requirements in the corresponding HKFRS Accounting Standards to report the effects of uncertainties in the financial statements using climate-related examples. Therefore, the amendments do not have an effective date or transitional provisions. The amendments did not have any impact on the Group’s financial statements.

3. OPERATING SEGMENT INFORMATION

The Group is primarily engaged in the pharmaceutical direct sales business, pharmaceutical e-commerce platform business and healthcare and digital services business. Given that the chief operating decision maker of the Company considers that the Group’s business is operated and managed as a single segment of distribution and development of pharmaceutical and healthcare business, no further segment information is presented.

Geographical information

During the year ended March 31, 2026, all (2025: all) of the Group’s revenue from external customers and over 99% (2025: over 99%) non-current assets other than financial instruments and deferred tax assets as at March 31, 2026 attributed to Chinese mainland as determined based on the locations of customers and assets, respectively.

3. OPERATING SEGMENT INFORMATION (CONTINUED)

Information about a major customer

During the year ended March 31, 2026, there was no revenue derived from transactions with a single external customer which amounted to 10% or more of the Group's revenue (2025: Nil).

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue from contracts with customers is as follows:

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Pharmaceutical direct sales business	29,664,989	26,124,420
Pharmaceutical e-commerce platform business	3,638,466	3,588,499
Healthcare and digital services business	951,667	885,373
Total	<u>34,255,122</u>	<u>30,598,292</u>

(i) Disaggregated revenue information

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Types of goods or services:		
Sale of products	26,925,462	24,058,732
Provision of services	7,329,660	6,539,560
Total	<u>34,255,122</u>	<u>30,598,292</u>
Timing of revenue recognition:		
At a point in time	28,859,878	26,190,523
Over time	5,395,244	4,407,769
Total	<u>34,255,122</u>	<u>30,598,292</u>

The following table shows the amounts of revenue recognized in the reporting period that were included in the contract liabilities at the beginning of the reporting period:

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Sale of products	287,524	154,875
Provision of services	407,571	399,808
Total	<u>695,095</u>	<u>554,683</u>

4. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

(ii) Performance obligations

Information about the Group's performance obligations is summarized below:

Sale of products

The performance obligation is satisfied upon delivery of the pharmaceutical and healthcare products. For B2C pharmacy sales, payment is received from the payment platform, i.e. Alipay.com Co., Ltd. (支付寶(中國)網絡技術有限公司) (“Alipay”), when the receipt of goods is confirmed by customers or by the payment platform automatically within a pre-specified period of time after delivery. For B2B pharmacy sales, payment is generally due within 30 to 90 days, except for new customers, where payment in advance is normally required. Some contracts provide customers with a right of return which gives rise to variable consideration subject to constraint.

Provision of services

The performance obligation is satisfied over time or at a point in time as marketing services, outsourced and value-added services, E-commerce platform services, healthcare and digital services, and marketing materials review and value-added services are rendered. Payment is generally received upon the completion of the underlying transactions, prior to the provision of services on a full prepayment basis, or due within 30 to 90 days.

The Group has elected the practical expedient for not to disclose the remaining performance obligations because the performance obligations are part of contracts with original expected duration of one year or less (2025: one year or less) or the Group has a right to consideration from the customer in an amount that corresponds directly with the value to the customer of the Group's performance completed to date.

4. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Other income		
Bank interest income	463,430	464,654
Other interest income	—	195
Investment income	12,661	4,125
Management fee income from a joint venture	11,475	12,193
Dividend income	11,988	19,600
Government grants [#]	55,812	103,745
Sublease income	18,636	194
Others	11,103	4,892
	<u>585,105</u>	<u>609,598</u>
Total other income		
Gains		
Fair value gains on financial assets at fair value through profit or loss	—	51,364
Gain on partial disposal of financial assets at fair value through profit or loss	67,055	—
Gain on partial disposal of associates	37,653	—
Gain on deemed disposal of interests in associates	226,176	1,633
Gain on deemed investment of an associate	2,630	—
Gain on disposal of a business	9,538	—
Foreign exchange differences, net	32,343	—
Gain on disposal of property and equipment	—	641
Gain on revision of lease terms arising from changes in the non-cancellable periods of leases	41	—
	<u>375,436</u>	<u>53,638</u>
Total gains		
Total other income and gains	<u>960,541</u>	<u>663,236</u>

[#] Government grants mainly represented incentives received for investments in certain regions in Chinese mainland in which the Company's subsidiaries operate as well as tax-related benefits. There are no unfulfilled conditions or contingencies relating to these government grants.

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Cost of goods sold*	23,254,086	20,726,222
Cost of services provided* (excluding employee benefit expense)	2,593,653	2,285,440
Depreciation of property and equipment	13,986	15,295
Depreciation of right-of-use assets	22,456	25,471
Amortization of intangible assets	16,799	16,839
Fair value losses on financial assets at fair value through profit or loss**	415,103	—
Loss on partial disposal of associates**	—	42,423
Loss on disposal of property and equipment**	389	—
Loss on disposal of intangible assets**	192	22
Foreign exchange differences, net**	—	37,143
Impairment of goodwill**	5,516	—
Impairment of investments in associates**	94,478	410,020
Provision of inventories*	130,748	92,398
Lease payments not included in the measurement of lease liabilities	1,454	2,131
Impairment of financial assets, net**:		
Impairment of trade receivables	975	6,207
Impairment of financial assets included in prepayments, other receivables and other assets	—	11,174
Total	<u>975</u>	<u>17,381</u>
Loss on revision of lease terms arising from changes in the non-cancellable periods of leases**	—	32
Auditor's remuneration	4,300	4,230
Employee benefit expense (including directors' and chief executive's remuneration):		
Wages, salaries and social welfare benefits	625,871	565,932
Discretionary performance related bonuses	119,992	222,249
Share-based compensation expense	162,124	224,535
Pension scheme contributions [#]	42,810	55,179
Total	<u>950,797</u>	<u>1,067,895</u>

* These items are included in "Cost of sales" in the consolidated statement of profit or loss.

** These items are included in "Other expenses and losses" in the consolidated statement of profit or loss.

[#] There are no forfeited contributions that may be used by the Group as the employer to reduce the existing level of contributions.

6. INCOME TAX

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Current — Hong Kong profits tax		
Charge for the year	10,819	8,461
Overprovision in prior years	(5)	(6)
Current — Chinese mainland income tax		
Charge for the year	281,724	130,074
Deferred	45,340	(10,575)
	<u>337,878</u>	<u>127,954</u>
Total tax charge for the year	<u>337,878</u>	<u>127,954</u>

Hong Kong profits tax has been provided at the rate of 16.5% (2025: 16.5%) on the estimated assessable profits arising in Hong Kong.

In Chinese mainland, the companies are subject to the PRC corporate income tax rate of 25% (2025: 25%), except for two (2025: two) PRC subsidiaries which are entitled to a preferential tax rate of 15% (2025: 15%) because they are regarded as High and New Technology Enterprises and one (2025: one) PRC subsidiary which is entitled to a preferential tax rate of 15% because it operates in Hainan Free Trade Port and meets the preferential tax treatment requirements.

No tax attributable to the joint venture was included in “Share of profit or loss of a joint venture” in the consolidated statement of profit or loss (2025: Nil).

The share of tax charge attributable to associates of approximately RMB1,155,000 (2025: RMB949,000) is included in “Share of profits or losses of associates” in the consolidated statement of profit or loss.

7. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the year attributable to ordinary equity holders of the parent of RMB1,936,162,000 (2025: RMB1,432,427,000), and the weighted average number of ordinary shares of 16,110,469,738 outstanding during the year (2025: 16,070,669,722).

The calculation of the diluted earnings per share amounts is based on the profit for the year attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the year, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise of all dilutive potential ordinary shares into ordinary shares.

The calculations of basic and diluted earnings per share are based on:

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	<u>1,936,162</u>	<u>1,432,427</u>
	Number of shares	
	2026	2025
Shares		
Weighted average number of ordinary shares outstanding during the year used in the basic earnings per share calculation	16,110,469,738	16,070,669,722
Effect of dilution — weighted average number of ordinary shares:		
Share options	2,115,329	1,696
Restricted share units	<u>86,339,942</u>	<u>65,132,486</u>
Total	<u>16,198,925,009</u>	<u>16,135,803,904</u>

8. DIVIDENDS

The board of directors of the Company recommends the payment of a final dividend of RMB5.95 cents (2025: Nil) per ordinary share and a special dividend of RMB13.52 cents (2025: Nil) per ordinary share for the year ended March 31, 2026, subject to approval by the shareholders of the Company at the forthcoming annual general meeting of the Company. The total proposed dividend for the year ended March 31, 2026 is RMB3,140,000,000 (2025: Nil).

9. TRADE AND BILLS RECEIVABLES

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Trade receivables	1,269,116	1,083,331
Impairment	<u>(36,571)</u>	<u>(36,255)</u>
Net carrying amount	1,232,545	1,047,076
Bills receivable	<u>33,345</u>	<u>5,447</u>
Total trade and bills receivables	<u><u>1,265,890</u></u>	<u><u>1,052,523</u></u>

The Group's trading terms with some of its customers are on credit. The Group provides a credit period of 30 to 90 days. Trade receivables are settled in accordance with the terms of the respective contracts. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

Included in the Group's trade receivables are amounts due from subsidiaries of Alibaba Group (excluding the Group) of approximately RMB470,439,000 (2025: RMB502,821,000) and the Group's associates of approximately RMB189,000 (2025: RMB194,000), which are repayable on credit terms mutually agreed by the parties involved.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the date of products delivered to B2C customers or received by B2B customers, or services rendered to customers and net of impairment, is as follows:

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Within 3 months	1,191,617	936,079
4 to 12 months	27,292	96,636
Over 1 year	<u>13,636</u>	<u>14,361</u>
Total	<u><u>1,232,545</u></u>	<u><u>1,047,076</u></u>

At March 31, 2026, the Group's bills receivable would be mature within 6 months (2025: 6 months).

9. TRADE AND BILLS RECEIVABLES (CONTINUED)

The movements in the loss allowance for impairment of trade receivables are as follows:

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
At April 1	36,255	33,687
Impairment (<i>note 5</i>)	975	6,207
Amount written off as uncollectible	<u>(659)</u>	<u>(3,639)</u>
At March 31	<u><u>36,571</u></u>	<u><u>36,255</u></u>

10. TRADE AND BILLS PAYABLES

An ageing analysis of the trade and bills payables as at the end of the reporting period, based on the date of products and services received by the Group or the date of bill issuance, is as follows:

	2026 <i>RMB'000</i>	2025 <i>RMB'000</i>
Within 3 months	2,405,438	2,671,256
4 to 12 months	454,388	147,870
Over 1 year	<u>169,948</u>	<u>33,255</u>
Total	<u><u>3,029,774</u></u>	<u><u>2,852,381</u></u>

The trade payables are non-interest-bearing and are normally settled on terms of 30 to 90 days.

Included in the Group's trade payables are amounts due to subsidiaries of Alibaba Group (excluding the Group) of approximately RMB283,721,000 (2025: RMB495,487,000), which are repayable on credit terms mutually agreed by the parties involved.

11. EVENTS AFTER THE REPORTING PERIOD

The Group did not have any significant events subsequent to March 31, 2026.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company strives to attain and maintain high standards of corporate governance continuously as it believes that effective corporate governance practices are fundamental to safeguarding the interests of its shareholders and other stakeholders, and to enhancing shareholder value. The Company has adopted the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

In the opinion of the Board, throughout the Reporting Period, the Company has complied with the code provisions (“**Code Provision(s)**”) set out in the Corporate Governance Code under Appendix C1 to the Listing Rules, except in respect of the following matters:

Code Provision C.2.1 stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Accordingly, the appointment of Mr. Shen Difan, an executive Director and the Chief Executive Officer of the Company, as the chairman of the Board with effect from December 15, 2025 deviates from the relevant Code Provision. The Board believes that the current leadership structure provides the Company with continuity of experience, strong and consistent leadership, and a unified voice in articulating the Company’s business and strategy. At the same time, the Board upholds an active oversight framework with robust checks and balances to protect the interests of the Company and its shareholders. The Board will continue to assess the effectiveness of the Company’s leadership structure while fulfilling its fiduciary duty to determine the governance structure that best serves the interests of the Shareholders.

Code Provision D.1.2 stipulates that management should provide all members of the Board with monthly updates giving a balanced and understandable assessment of the Company’s performance, position and prospects in sufficient details to enable the Board as a whole and each Director to discharge their duties under Rule 3.08 and Chapter 13 of the Listing Rules. The Company from time to time, based on business needs and conditions, provides to the Board up-to-date business information and convenes ad hoc meetings for considering material business or management issues, so as to enable the Directors and the Board as a whole to discharge their duties.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted its own code for securities transactions by the (i) Directors; and (ii) certain officers and employees of the Company or its subsidiaries that are considered to be likely in possession of unpublished inside information in relation to the Company or its securities, on terms not less exacting than those in the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix C3 to the Listing Rules.

In response to specific enquiries made by the Company to all Directors, all Directors have confirmed that they have complied with the Model Code and the Company's code for securities transactions throughout the Reporting Period.

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY

During the Reporting Period, neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities (including any sale of treasury shares).

As at March 31, 2026, there were no treasury shares held by the Company.

AUDIT COMMITTEE REVIEW

The Group's annual results for the Reporting Period have been reviewed by the Audit Committee. The Audit Committee has also discussed auditing, internal control and financial reporting matters including the review of accounting practices and principles adopted by the Group.

SCOPE OF WORK OF ERNST & YOUNG ON THE PRELIMINARY RESULTS ANNOUNCEMENT

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss, consolidated statement of comprehensive income and the related notes thereto for the Reporting Period as set out in this preliminary results announcement have been agreed by the Group's auditors, Ernst & Young, to the amounts set out in the Group's consolidated financial statements for the Reporting Period. The work performed by Ernst & Young in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the HKICPA and consequently no assurance has been expressed by Ernst & Young on the preliminary results announcement.

PUBLICATION OF PRELIMINARY RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.irasia.com/listco/hk/alihealth). The annual report for the Reporting Period containing the information as required by Appendix D2 to the Listing Rules will be dispatched to the Shareholders and available on the above websites in due course.

For and on behalf of the Board
Alibaba Health Information Technology Limited
Shen Difan
Chairman and Chief Executive Officer

Hong Kong, May 14, 2026

As at the date of this announcement, the Board comprises Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.

[^] *For identification purposes only*